|
|
| News Archive |
OGT Signs Licensing Deal for Colorectal Cancer Biomarkers
Thursday, February 23, 2012
OGT has entered into an exclusive licensing agreement with Inven2.
Biodegradable Nanoparticles of mPEG-PLGA-PLL Triblock Copolymers as Novel Non-Viral Vectors for Improving siRNA Delivery and Gene Silencing
Wednesday, February 22, 2012
The gene silencing efficiency of mPEG-PLGA-PLL NPs is shown to be higher than that of commercially available transfecting agent Lipofectamine, while showing no cytotoxicity. The purpose of this work was to synthesize the novel biodegradable mPEG-PLGA-PLL NPs encapsulating siRNA, and examine the physical properties of NPs and in vitro siRNA release profile from NPs.
Expression Analysis Announces RNA-SEQ Grant Program
Tuesday, February 21, 2012
EA teams with Golden Helix and Illumina to offer three fully-funded grants for RNA-Seq studies.
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of Debio 0932
Tuesday, February 21, 2012
Company expects to initiate a combination Phase I/II study in NSCLC patients in the second quarter of 2012.
PRECOS to Unveil New Service Portfolio at Cancer Targets & Therapeutics and AACR 2012
Tuesday, February 21, 2012
2012 conference examines new and emerging targets and therapeutics in the area of cancer research.
PRECOS Appoints Dr Martin Page as Scientific Consultant
Tuesday, February 21, 2012
Appointment reinforces the ambition of PRECOS to contribute to the growing cancer therapy market.
Sol-Gel Signs $27 M Deal for Dermatology Drug Delivery
Tuesday, February 21, 2012
Company has entered into a second development and licensing agreement with a leading U.S. pharmaceutical company.
Critical Pharmaceuticals and The University of Nottingham to Develop Nano-Enabled Nasal Spray for Osteoporosis
Thursday, February 16, 2012
The Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC) provide grant funding to support the £545,000 project.
EPI Collaborates with the University of Texas MD Anderson Cancer Center
Tuesday, February 14, 2012
EPI collaborates on Liquid Tissue® personalized medicine assays in lung cancer treatment.
|
|
|
| << | 1 2 3 4 5 6 7 | >> | | Showing Results 1 - 10 of 1697 |
|
|
